Previous 10 | Next 10 |
Ventyx to host virtual investor event on March 11 th to provide clinical updates on our NLRP3 portfolio and from the open-label extension of the VTX002 Phase 2 trial in ulcerative colitis Cash, cash equivalents and marketable securities of $252.2 million as of December 31, 2...
A look at the top 10 most actives in the United States Greenbrook TMS Inc. (GBNH) rose 64.9% to $0.32 on volume of 109,974,769 shares PROSHARES TRUST (SQQQ) rose 3.7% to $12.36 on volume of 106,443,308 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) rose 4.7% to $4.825 on volume...
2024-02-21 12:27:34 ET More on Mid-day movers & stocks. Janux Therapeutics: Precision Immunotherapy, But Overpriced For Such An Early Stage Greenbrook TMS secures $1.5M in debt financing Compass Pathways and Greenbrook TMS enter into three-year research collabora...
2024-02-21 11:26:20 ET More on Ventyx Biosciences Ventyx: Too Risky Right Now After Some Poor Data Seeking Alpha’s Quant Rating on Ventyx Biosciences Historical earnings data for Ventyx Biosciences Financial information for Ventyx Biosciences ...
2024-02-21 10:06:30 ET DENVER, Colo., Feb 21, 2024 (www.247marketnews.com)- The following companies published announcements or are trading higher on higher-than-usual volume; (NASDAQ: BREA ), (NASDAQ: MOTS ), (NASDAQ: SEED ), (NASDAQ: VTYX ), (NASDAQ: LUNR ) News ...
2024-02-21 10:00:32 ET More on Health Care Select Sector SPDR XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming UBS concedes it wasn't bullis...
SAN DIEGO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announ...
2024-01-18 16:55:37 ET Gainers: Ventyx Biosciences ( VTYX ) +6% . EyePoint Pharmaceuticals ( EYPT ) +3% . HashiCorp ( HCP ) +3% . Nubia Brand International ( NUBI ) +2% . Microvision ( MVIS ) +2% . Losers: Spectaire...
2024-01-18 08:36:24 ET Summary Ventyx Biosciences has a mid-stage pipeline targeting inflammatory diseases, with lead assets VTX958, VTX002, and VTX2735. Phase 1 data for VTX958 showed high selectivity and excellent safety profile, but phase 2 trial results did not meet internal t...
2024-01-11 16:37:35 ET Gainers: Ventyx Biosciences ( VTYX ) +6% . EyePoint Pharmaceuticals ( EYPT ) +3% . HashiCorp ( HCP ) +3% . Nubia Brand International ( NUBI ) +2% . Microvision ( MVIS ) +2% . Losers: Spectaire...
News, Short Squeeze, Breakout and More Instantly...
Ventyx Biosciences Inc. Company Name:
VTYX Stock Symbol:
NASDAQ Market:
Ventyx Biosciences Inc. Website:
A look at the top 10 most actives in the United States Freight Technologies Inc. (FRGT) rose 10.4% to $0.6899 on volume of 220,478,071 shares Nauticus Robotics Inc. (KITT) rose 23.2% to $0.17 on volume of 217,326,595 shares GameStop Corporation (GME) rose 47.5% to $46.55 on volume of 178,...
VTX3232 demonstrated improvements in body weight, systemic inflammatory biomarkers and cardiometabolic parameters in diet-induced obesity (DIO) mice Additive effects were observed for VTX3232 in combination with the GLP-1 receptor agonist semaglutide across key endpoints compared to semag...
SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced th...